



NEUSTADT RESUMES ROLE AS EXECUTIVE CHAIRMAN

29th June 2012, Sydney: The Board of SomnoMed Limited announced today that, as part of the previously announced changes in its top management structure, Dr. Peter Neustadt would resume the role of Executive Chairman with management responsibility for the SomnoMed group until further notice.

Dr. Neustadt previously filled the role as Executive Chairman from December 2006 to December 2008 and handed executive management responsibility to Mr. Ralf Barschow on 1st of January 2009. Mr. Barschow was appointed CEO of SomnoMed in September 2007.

“We have appointed a top line US recruitment firm to assist us in filling the new positions of President SomnoMed Inc., responsible for our business in North America, of Chief Medical Officer and of Senior Account Manager HMO responsible for the development of SomnoMed’s relationships and business with US health insurers. Parallel to that we are also in process of strengthening our marketing and sales capabilities in our medical department. We expect to make announcement about appointments in the coming months,” said Neustadt.

“Our European and APAC businesses are not directly affected by the changes taking place. I will work closely with our management in these regions, continuing to build the acceptance of oral appliance treatment and the application of SomnoDent[®] as the globally leading product in our field. However, also in these regions we will see more focus on growing the acceptance of the SomnoDent[®] treatment from medical specialists and the referral of patients to our educated SomnoMed Preferred Network Dentists.”

This is in line with most encouraging results of recent clinical research, strengthening the case that the SomnoDent[®] oral appliance treatment of sleep apnea is effective and offers a most patient friendly alternative to CPAP for most patients with light and moderate conditions and especially all patients who are rejecting CPAP or are non-compliant in its regular, nightly use.

“The job ahead is to position SomnoMed and its leading SomnoDent[®] products firmly in the mainstream of the medical device industry treating patients with sleep disordered breathing problems, in particular obstructive sleep apnea. This should allow us to accelerate our growth substantially over the next three to five years. The base to achieve our medium-long term objectives has been built over the last five years. We can now move decisively forward establishing SomnoMed amongst the leading medical device companies in our space,” said Neustadt.

Contact:

Dr. Peter Neustadt
Chairman, SomnoMed Limited
Ph +61 2 9467 0400 or +61 (0) 414 566 592-m